Akari Therapeutics, Plc
AKTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -637,061.53% | -17,684.99% | -12,705.14% | -14,576.21% |
| EV / EBITDA | 0.05 | 0.62 | 0.20 | -0.19 |
| Quality | ||||
| ROIC | -5.92% | -8.83% | -11.05% | -12.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.33 | 1.72 | 0.58 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 35.45% | -51.44% | -1.22% | -42.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.63 | 0.20 | -0.18 |
| Interest Coverage | -18.38 | -62.38 | -64.09 | -34.64 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -1,116,630.00 |